Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
- Status
- COMPLETED
- Phase
- N/A
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1